Completed PHASE1 INTERVENTIONAL 3-arm NCT01047605

Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers (NCAG 5209)

Evaluation of the Pharmacological Effects of NEURAPAS® Balance and PASCOFLAIR® 425 mg by Quantitative Measurement of Brain Activity in 16 Healthy Volunteers. A Single-blinded, Randomised, Placebo-controlled, 3-armed Phase-I-study With Cross-over Design

Sponsor: Pascoe Pharmazeutische Praeparate GmbH

Conditions Healthy

Interventions Neurapas balance P-Tabletten weiß Pascoflair 425 mg

Updated 5 times since 2017 Last updated: May 14, 2010 Started: Jan 31, 2010 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01047605, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Pascoe Pharmazeutische Praeparate GmbH, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pascoe Pharmazeutische Praeparate GmbH

Data source: Pascoe Pharmazeutische Praeparate GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wetzlar, Germany